Editorial

newsfeed

We have compiled a pre-selection of editorial content for you, provided by media companies, publishers, stock exchange services and financial blogs. Here you can get a quick overview of the topics that are of public interest at the moment.
360o
Share this page
News from the economy, politics and the financial markets
In this section of our news section we provide you with editorial content from leading publishers.

TRENDING

Latest news

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Rocket Lab USA, Inc. of Class Action Lawsuit and Upcoming Deadlines – RKLB

NEW YORK, March 30, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Rocket Lab USA, Inc (“Rocket Lab” or the “Company”) (NASDAQ: RKLB).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased. The class action concerns whether Rocket Lab and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. You have until April 28, 2025 to ask the Court to appoint you as Lead Plaintiff for the class if you purchased or otherwise acquired Rocket Lab securities during the Class Period. A copy of the Complaint can be obtained at www.pomerantzlaw.com.          [Click here for information about joining the class action] On February 25, 2025, Bleeker Street Research (“Bleeker Street”) published a report alleging, among other things, that Rocket Lab “has materially misled investors about the likelihood that its Neutron rocket will launch in mid-2025.” The report revealed that the Company’s plans for three barge landing tests, which were originally scheduled to occur in a window between September 2024 and March 2025, had been pushed back to a window beginning in September 2025 and could occur as late as March 2026. The report further revealed significant delays in preparing the Company’s launch pad, including a potable water problem not scheduled to be fixed until January 2026, which would delay launch further. The report also alleged that Company’s only Neutron contract so far is with an “unreliable startup” named E-Space which is described as “risk item.” The report further alleged this “contract is not a full-price deal, contrary to what Rocket Lab has said.” Following publication of the Bleeker Street report, Rocket Lab’s stock price fell $2.21 per share, or 9.83%, to close at $20.28 per share on February 25, 2025. Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com. Attorney advertising.  Prior results do not guarantee similar outcomes.   CONTACT:Danielle PeytonPomerantz LLPdpeyton@pomlaw.com646-581-9980 ext. 7980  The post INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Rocket Lab USA, Inc. of Class Action Lawsuit and Upcoming Deadlines – RKLB appeared first on ForexTV.

Read More

Ambia Solar Headquarters Move to Lindon, Utah

New Location Marks a Milestone in Commitment to Continued Growth LINDON, Utah, March 29, 2025 (GLOBE NEWSWIRE) -- Ambia Solar, a leading residential solar company known for its commitment to personalized energy solutions and customer-first service, is proud to announce the relocation of its corporate headquarters to Lindon, Utah. The official move took place on Friday, March 28, 2025. The new headquarters will serve as a central hub for Ambia’s operations, providing expanded space for its growing teams in sales, operations, finance, and customer service. This move reflects Ambia’s continued growth and commitment to creating a collaborative, forward-thinking workplace to support its mission of making clean, dependable energy accessible for homeowners across the country. Conner Ruggio, CEO of Ambia, shared that from the first time he walked through the building—formerly home to the successful HR company BambooHR—he had a gut feeling it was the right fit for Ambia. “I genuinely believe this is going to be a place where we do some incredible things,” Ruggio said. “I hope this is a place you love to work every day. I know that I will.” Located in the heart of Utah County, the new facility offers greater accessibility, enhanced amenities, and plenty of space for future growth as Ambia continues scaling its efficient energy solutions throughout the U.S. This move underscores the company’s ongoing investment in its employees and communities, creating opportunities for job growth, collaboration, and impact across the solar industry. About Ambia SolarAmbia is a residential solar company dedicated to helping homeowners achieve greater energy independence through smart, reliable solar solutions. With a focus on transparency, education, and world-class service, Ambia manages each project in-house—from consultation and system design to professional installation and support. Ambia currently operates in nine states with plans for continued expansion. Contact:Anne HeathMarketing & Communicationsanne.heath@ambiasolar.comwww.ambiasolar.com A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/596c2ea7-46a0-49da-bc36-2b3e62b5f99e The post Ambia Solar Headquarters Move to Lindon, Utah appeared first on ForexTV.

Read More

ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Intellia Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – NTLA

NEW YORK, March 29, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Intellia Therapeutics, Inc. (NASDAQ: NTLA) between July 30, 2024 and January 8, 2025, both dates inclusive (the “Class Period”), of the important April 14, 2024 lead plaintiff deadline. SO WHAT: If you purchased Intellia securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO DO NEXT: To join the Intellia class action, go to   https://rosenlegal.com/submit-form/?case_id=35009 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email case@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 14, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers. DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, defendants provided investors with material information concerning Intellia’s Phase 1/2 study evaluating NTLA-3001 for the treatment of alpha-1 antitrypsin deficiency (AATD)-associated lung disease. Defendants’ statements included, among other things, confidence in Intellia’s timeline for the aforementioned study, specifically that Intellia expected to dose the first patient in the second half of 2024. Defendants failed to disclose inter alia that the demand for viral-based editing was rapidly dwindling as non-viral delivery methods became a main target of the scientific research community due to their cost-effectiveness and more efficient development, thus making NTLA-3001 an inefficient program for Intellia to maintain. When the true details entered the market, the lawsuit claims that investors suffered damages.To join the Intellia class action, go to https://rosenlegal.com/submit-form/?case_id=35009 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email case@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff. Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/. Attorney Advertising. Prior results do not guarantee a similar outcome. ------------------------------- Contact Information:         Laurence Rosen, Esq.        Phillip Kim, Esq.        The Rosen Law Firm, P.A.        275 Madison Avenue, 40th Floor        New York, NY 10016        Tel: (212) 686-1060        Toll Free: (866) 767-3653        Fax: (212) 202-3827        case@rosenlegal.com        www.rosenlegal.com The post ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Intellia Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – NTLA appeared first on ForexTV.

Read More

MPWR IMPORTANT DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Monolithic Power Systems, Inc. Investors to Secure Counsel Before Important April 7 Deadline in Securities Class Action – MPWR

NEW YORK, March 29, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Monolithic Power Systems, Inc. (NASDAQ: MPWR) between February 8, 2024 and November 8, 2024, both dates inclusive (the “Class Period”), of the important April 7, 2025 lead plaintiff deadline. SO WHAT: If you purchased Monolithic Power Systems common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO DO NEXT: To join the Monolithic Power Systems class action, go to   https://rosenlegal.com/submit-form/?case_id=34600 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email case@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 7, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers. DETAILS OF THE CASE: According to the lawsuit, defendants made materially false and/or misleading statements and/or failed to disclose that: (1) Monolithic Power Systems’ voltage regulator modules and power management integrated circuits were suffering from significant performance and air quality issues; (2) these defects had, in turn, negatively impacted the performance of certain products offered by Nvidia in which such products were used; (3) Monolithic Power Systems had failed to adequately address and resolve known issues affecting the performance of the power management solutions that it supplied to Nvidia; (4) Monolithic Power Systems’ relationship with Nvidia had been irreparably damaged due to the significant performance and quality control problems affecting the products it supplied to Nvidia and Monolithic Power Systems’ failure to adequately address such issues; and (5) as a result of the above, Monolithic Power Systems was acutely exposed to material undisclosed risks of significant business, financial, and reputational harm. When the true details entered the market, the lawsuit claims that investors suffered damages. To join the Monolithic Power Systems class action, go to   https://rosenlegal.com/submit-form/?case_id=34600 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email case@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff. Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/. Attorney Advertising. Prior results do not guarantee a similar outcome. ------------------------------- Contact Information:         Laurence Rosen, Esq.        Phillip Kim, Esq.        The Rosen Law Firm, P.A.        275 Madison Avenue, 40th Floor        New York, NY 10016        Tel: (212) 686-1060        Toll Free: (866) 767-3653        Fax: (212) 202-3827        case@rosenlegal.com        www.rosenlegal.com The post MPWR IMPORTANT DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Monolithic Power Systems, Inc. Investors to Secure Counsel Before Important April 7 Deadline in Securities Class Action – MPWR appeared first on ForexTV.

Read More

USD/CAD Weekly Forecast: Surprise Data Keeps Loonie Afloat

The USD/CAD weekly forecast indicates unexpected strength in Canada’s economy. US data this week came in higher than expected, easing fears of a recession. There is uncertainty over Trump’s looming tariffs. The USD/CAD weekly forecast indicates unexpected strength in Canada’s economy that is keeping the loonie afloat. Ups and downs of USD/CAD  The USD/CAD pair… […] The post USD/CAD Weekly Forecast: Surprise Data Keeps Loonie Afloat appeared first on ForexTV.

Read More

AUD/USD Weekly Forecast: Resilient Despite Tariffs, Eying RBA

The AUD/USD weekly forecast shows a resilient Aussie. Inflation in Australia increased by a smaller-than-expected 2.4%. Economists believe the RBA will keep rates unchanged. The AUD/USD weekly forecast shows a resilient Aussie as market participants gear up for the RBA meeting and Trump tariffs. Ups and downs of AUD/USD  The AUD/USD pair had a slightly… […] The post AUD/USD Weekly Forecast: Resilient Despite Tariffs, Eying RBA appeared first on ForexTV.

Read More

MODV IMPORTANT DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages ModivCare Inc. Investors to Secure Counsel Before Important March 31 Deadline in Securities Class Action – MODV

NEW YORK, March 29, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ModivCare Inc. (NASDAQ: MODV) between November 3, 2022 and September 15, 2024, both dates inclusive (the “Class Period”), of the important March 31, 2025 lead plaintiff deadline. SO WHAT: If you purchased ModivCare securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO DO NEXT: To join the ModivCare class action, go to https://rosenlegal.com/submit-form/?case_id=34493 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email case@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than March 31, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers. DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period made materially false and/or misleading statements as well as failed to disclose adverse facts about ModivCare’s business, operations, and prospects. Specifically, defendants failed to disclose that certain contracts used in ModivCare’s non-emergency medical transportation (“NEMT”) segment caused ModivCare’s free cash flow to deteriorate and that, as a result: (i) contract renegotiations and pricing accommodations negatively impacted ModivCare’s adjusted EBITDA; (ii) ModivCare had insufficient liquidity; and (iii) defendants’ positive statements about ModivCare’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages. To join the ModivCare class action, go to https://rosenlegal.com/submit-form/?case_id=34493 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email case@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff. Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/. Attorney Advertising. Prior results do not guarantee a similar outcome. ------------------------------- Contact Information:         Laurence Rosen, Esq.        Phillip Kim, Esq.        The Rosen Law Firm, P.A.        275 Madison Avenue, 40th Floor        New York, NY 10016        Tel: (212) 686-1060        Toll Free: (866) 767-3653        Fax: (212) 202-3827        case@rosenlegal.com        www.rosenlegal.com The post MODV IMPORTANT DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages ModivCare Inc. Investors to Secure Counsel Before Important March 31 Deadline in Securities Class Action – MODV appeared first on ForexTV.

Read More

SFJ Pharmaceuticals & SERB Pharmaceuticals Present Positive Final Results from Pivotal Ph 3 REVERSE-IT Trial of Bentracimab for the Reversal of Antiplatelet Effects of Ticagrelor in Patients Requiring Surgery or Experiencing Major Bleeding

- Phase 3 trial achieved primary endpoint, quickly and safely restoring platelet function in ticagrelor-treated patients undergoing urgent surgery or experiencing major bleeding PLEASANTON, CA, March 29, 2025 (GLOBE NEWSWIRE) -- SFJ Pharmaceuticals (SFJ) and SERB Pharmaceuticals (SERB) announced today the final results of the pivotal Phase 3 REVERSE-IT trial designed to study the reversal of the antiplatelet effects of ticagrelor with bentracimab - a human monoclonal antibody fragment (Fab) that targets ticagrelor and its active metabolite specifically - in patients in need of urgent surgery or an invasive procedure or experiencing major bleeding. The trial achieved its primary endpoint, demonstrating significant, rapid restoration of platelet function in both patients requiring urgent surgery as well as those with major bleeding.1  The primary efficacy endpoint of the REVERSE-IT trial was minimum percent inhibition of P2Y12 reactivity units (PRU) within four hours after start of bentracimab infusion, compared to baseline.1 The mean difference in the primary efficacy endpoint was -122.94 (P<0.0001) and the mean (standard deviation) PRU increased from 91.7 (79.78) pre-treatment to ≥180 (lower limit of normal PRU value) within 5-10 minutes (P<0.0001) and remained ≥180 throughout the 16-hour infusion and ≥8 hours thereafter.1  The trial also achieved its secondary efficacy endpoint with 94.3% of eligible patients, 100% of patients requiring urgent surgery and 83.1% of patients experiencing major bleeding, achieving effective (excellent or good) hemostasis within 24 hours as assessed using GUSTO bleeding criteria in the surgery group and Connolly criteria in the bleeding group.1  “These Phase 3 data demonstrate that bentracimab could be an effective option to manage major or life-threatening bleeding in patients on ticagrelor, with a consistent safety profile,” said Dr. Deepak L. Bhatt, MD, MPH, MBA, Director of the Mount Sinai Fuster Heart Hospital and the Dr. Valentin Fuster Professor of Cardiovascular Medicine at the Icahn School of Medicine at Mount Sinai, Principal Investigator on the Phase 3 REVERSE-IT trial, and a paid consultant for SFJ Pharmaceuticals. “Discontinuation of ticagrelor and waiting for its anti-platelet effects to disappear over three to five days is not always feasible when patients require urgent surgery or are experiencing major bleeding. Bentracimab’s ability to normalize platelet function within 5-10 minutes and maintain normal platelet function throughout the infusion to facilitate hemostasis delivers a much-needed solution to better manage patients in need.”  Bentracimab also demonstrated an overall favorable safety profile and was generally well tolerated.1 No serious adverse reactions or allergic reactions occurred in patients treated with bentracimab.1 The rate of thrombotic events in this study (4.0%) was similar to the typical baseline for patients' underlying conditions.1 Ticagrelor was reinitiated or other P2Y12 inhibitors were started in 69.5% patients within 7 days after the bentracimab infusion.1  “The rapid onset of action of bentracimab and its relatively short half-life allows for the quick normalization of platelet function when needed. Stopping bentracimab after surgery or once an acute medical event is under control restores the desired anti-platelet effect of ticagrelor. This would allow doctors to manage both the risk of bleeding and the risk of thrombosis, increasing the value proposition of this medicine,” said Dr. Barbara White, President and Chief Executive Officer of SFJ.   “There is a significant unmet need to reverse ticagrelor’s effects in patients who require non-deferrable surgery or experience major bleeding,” said Vanessa Wolfeler, Chief Executive Officer, SERB Pharmaceuticals. “These results reinforce the promise of bentracimab, and SERB is committed to bringing this product to healthcare providers treating patients facing rare emergencies and conditions.”  These data were presented at the American College of Cardiology Annual Scientific Session in the Late-Breaking Clinical Trials session on March 29, 2025, from 11:30 a.m. to 12:30 p.m. CT, and are consistent with previous data and past studies. Phase 1 data regarding bentracimab were published in the New England Journal of Medicine in 2019,2 and the first interim analysis of the REVERSE-IT trial were published in the New England Journal of Medicine Evidence in 2021.3 Bentracimab received Breakthrough Therapy Designation from the FDA in 2019, was granted Priority Review in 2024 and Orphan Drug Designation on March 18, 2025.   About the REVERSE-IT Trial   The Phase 3 REVERSE-IT trial is a multi-center, open-label, prospective single-arm study of reversal of the antiplatelet effects of ticagrelor with bentracimab in patients who require urgent surgery or invasive procedure or are experiencing major bleeding.1 The trial enrolled 226 patients across the United States, Canada, the European Union and China.1 On Day 1, patients received an intravenous (IV) infusion comprised of an initial IV bolus of 6 grams (g) infused over 10 minutes for rapid reversal, followed immediately by a 6g IV loading infusion over four hours and then a 6g IV maintenance infusion over 12 hours.1  About Ticagrelor (BRILINTA®)  Ticagrelor, marketed by AstraZeneca as BRILINTA®, is P2Y12 platelet inhibitor indicated: 1) to reduce the risk of cardiovascular death, myocardial infarction (MI), and stroke in patients with acute coronary syndrome (ACS) or a history of MI. BRILINTA® also reduces the risk of stent thrombosis in patients who have been stented for treatment of ACS; 2) to reduce the risk of a first MI or stroke in patients with coronary artery disease at high risk for such events; and 3) to reduce the risk of stroke in patients with acute ischemic stroke or high-risk transient ischemic attack.  About SFJ Pharmaceuticals  SFJ is a global drug development company, which provides a unique and highly customized clinical development partnering model for the world’s top pharmaceutical and biotechnology companies. SFJ provides at-risk funding and the global clinical development management and oversight necessary for regulatory submission for some of the most promising drug development programs of pharmaceutical and biotechnology companies. SFJ’s mission is to leverage its financial strength and global team of pharmaceutical development experts to accelerate the development of life-saving and life-enhancing drugs for the benefit of physicians and the patients they serve. www.sfj-pharma.com   About SERB Pharmaceuticals  SERB acquired exclusive U.S. rights to RETRIG from SFJ in 2023 and will commercialize RETRIG in the U.S. The company equips healthcare providers worldwide with life-saving medicines for rare conditions and emergencies. For over 30 years we have consistently provided emergency medicines, medical countermeasures, and the world’s leading portfolio of antidotes. With a strong presence in the U.S., Europe, and the Middle East, along with a global network of distribution partners, we make essential medicines available in over 100 countries. Our proven ability to acquire, develop, manufacture, launch and commercialize specialist medicines allows us to meet critical medical needs with urgency. By expanding our reach through selective acquisitions and entering new markets, we’re not just supplying medicine; we’re raising the standard of care for more patients around the world. Learn more at https://SERB.com.  For further information contact:  SFJ Pharmaceuticals: Jonathan DeBenedetto, Chief Financial Officer admin@sfj-pharma.com; Tel: +1-925-223-6233  SERB Pharmaceuticals: Chris Sampson, Director of Corporate Communications chris.sampson@serb.com; Tel: +44 (0)7773 251 178  Media: Jaryd Leady, Spectrum Science Communications, jleady@spectrumscience.com; Tel: +1-856-803-7855   References  Bhatt DL. The Main Results of the Phase 3 REVERSE-IT Trial. Late-Breaking Clinical Trials II [Session 103]. In: American College of Cardiology’s Annual Scientific Session & Expo; March 29-31, 2025; Chicago, IL.  Bhatt DL, Pollack CV, Weitz JI, et al. Antibody-Based Ticagrelor Reversal Agent in Healthy Volunteers. N Engl J Med. 2019;380(19):1825-1833. doi:10.1056/NEJMoa1901778  Bhatt DL, Pollack CV, Mazer CD, et al. Bentracimab for Ticagrelor Reversal in Patients Undergoing Urgent Surgery. NEJM Evidence. 2022;1(3). doi:10.1056/evidoa2100047  CONTACT: Chris Sampson, DIrector of Corporate Communications SERB Pharmaceuticals +44 7773 251 178 chris.sampson@serb.com Jonathan DeBenedetto, Chief Financial Officer SFJ Pharmaceuticals +1-925-223-6233  admin@sfj-pharma.com Jaryd Leady Spectrum Science Communications  +1-856-803-7855 jleady@spectrumscience.com The post SFJ Pharmaceuticals & SERB Pharmaceuticals Present Positive Final Results from Pivotal Ph 3 REVERSE-IT Trial of Bentracimab for the Reversal of Antiplatelet Effects of Ticagrelor in Patients Requiring Surgery or Experiencing Major Bleeding appeared first on ForexTV.

Read More

ICLR DEADLINE NOTICE: ROSEN, A TOP RANKED LAW FIRM, Encourages ICON plc Investors to Secure Counsel Before Important April 11 Deadline in Securities Class Action – ICLR

NEW YORK, March 29, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of ordinary shares of ICON plc (NASDAQ: ICLR) between July 27, 2023 and October 23, 2024, both dates inclusive (the “Class Period”), of the important April 11, 2025 lead plaintiff deadline. SO WHAT: If you purchased ICON ordinary shares during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO DO NEXT: To join the ICON class action, go to https://rosenlegal.com/submit-form/?case_id=34903 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email case@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 11, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers. DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, defendants made false and misleading statements and/or failed to disclose that: (1) ICON was suffering from a material loss of business due to customer cost reduction measures and other widespread funding limitations impacting ICON’s client base; (2) ICON’s purported Functional Service Provision (“FSP”) and hybrid model offerings were insufficient to shield ICON from the adverse effects of a significant market downturn; (3) the requests for proposals ICON received from its biotechnology customers during the Class Period were used in substantial part as price discovery tools, and thus were not indicative of underlying client demand; (4) ICON’s customers had canceled contracts, limited or reduced engagements, delayed clinical trial work, and/or failed to enter into new contracts with ICON for additional clinical trial work at historical rates once existing projects ended (or were scheduled to end) in 2024; (5) ICON’s two largest customers were diversifying their clinical research organization (“CRO”) providers away from ICON; (6) as a result of the above, ICON’s reported net new business awards and book-to-bill metrics materially misrepresented client demand for ICON’s services; and (7) consequently, ICON was tracking materially below the 2024 revenue and earnings per share (“EPS”) guidance issued during the Class Period and such guidance lacked a reasonable factual basis. When the true details entered the market, the lawsuit claims that investors suffered damages. To join the ICON class action, go to https://rosenlegal.com/submit-form/?case_id=34903 call Phillip Kim, Esq. toll-free at 866-767-3653 or email case@rosenlegal.com for information on the class action. No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff. Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm. Attorney Advertising. Prior results do not guarantee a similar outcome. ------------------------------- Contact Information:         Laurence Rosen, Esq.        Phillip Kim, Esq.        The Rosen Law Firm, P.A.        275 Madison Avenue, 40th Floor        New York, NY 10016        Tel: (212) 686-1060        Toll Free: (866) 767-3653        Fax: (212) 202-3827        case@rosenlegal.com        www.rosenlegal.com The post ICLR DEADLINE NOTICE: ROSEN, A TOP RANKED LAW FIRM, Encourages ICON plc Investors to Secure Counsel Before Important April 11 Deadline in Securities Class Action – ICLR appeared first on ForexTV.

Read More

Financial Results for the Fourth Quarter of 2024

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES TORONTO, March 28, 2025 (GLOBE NEWSWIRE) -- Helios Fairfax Partners Corporation (TSX: HFPC.U) today announced its financial results for the year ended December 31, 2024. All dollar amounts in this news release are expressed in U.S. dollars except as otherwise noted. The financial results are derived from the consolidated financial statements prepared using the recognition and measurement requirements of International Financial Reporting Standards as issued by the International Accounting Standards Board (“IFRS Accounting Standards”), except as otherwise noted. Management Commentary “In 2024, we further advanced our strategy by deploying $55 million across high-growth sectors and divesting a key Legacy Non-Core asset for $16.3 million,” said Tope Lawani and Babatunde Soyoye, Co-CEOs of Helios Fairfax Partners. “Our investments contributed to the advancement of a number of new and exciting businesses including PFL Africa, a new regional league of the rapidly-growing Professional Fighters League; SeamlessHR, a Cloud-based HR and payroll platform digitizing employee lifecycle management; M2P Solutions, a rapidly expanding provider of infrastructure API and Banking-as-a-Service technology; and Moment, which offers integrated payments and other financial services to businesses and consumers. In the four years since the start of HFP’s relationship with Helios, the Helios Managed Investments have achieved an IRR of 14%. We remain committed to investment strategies that will enhance shareholder value while delivering on our mission to generate competitive returns through profitable, value-creating, and socially responsible businesses across Africa.” Highlights During the Fourth Quarter of 2024 Book value per share for the fourth quarter of 2024 was $3.84, compared to $4.23 in the third quarter of 2024. HFP reported a net loss of $41.6 million for the fourth quarter of 2024, compared to net earnings of $4.0 million in the third quarter of 2024. The decrease in book value per share compared to the third quarter of 2024 and the net loss in the fourth quarter were due to unrealized losses from the company’s investment in TopCo LP. These losses were offset by unrealized gains related to the Helios Managed Investments as well as interest and dividend income. Also contributing to the decrease in book value per share and net loss for the quarter was a loss on the forgiveness of the GP and management company loans and other expenses. HFP deployed $5.1 million under the loan facility with Digital Ventures during the quarter. HFP disposed of $16.3 million of Legacy Non-Core investments during the quarter, comprising $2.4 million for the sale of Indirect equity interest in AGH, $4.4 million for the sale of the AGH Loan, and $9.5 million for the sale of the Philafrica Facility. Financial Position and Results of Operations HFP reported a net loss of $41.6 million in the fourth quarter of 2024 as compared to a net loss of $80.9 million in the comparable period of 2023. The net loss includes $30.6 million of net losses on its investment in TopCo LP, partially offset by $12.8 million of net gains on its investment in Helios Managed Investments, and a $22.0 million loss on the forgiveness of the GP and management company loans and other expenses. The company reported a net loss of $58.8 million for the year ended December 31, 2024 compared to a net loss of $71.7 million for the year ended December 31, 2023. The net losses in 2024 and 2023 were driven primarily by unrealized losses on the company’s investment in TopCo. These unrealized losses were driven primarily by a decrease in carried interest expected to be received from TopCo Class A and by lower management fees for the Helios Strategies, which reduced the excess management fees to TopCo Class B. The unrealized losses were offset by unrealized gains related to Helios Managed Investments, due to the strong performance of the underlying investments in Helios Fund IV and Helios Sports and Entertainment Group. Also included in the net loss are expenses of $40.6 million, partially offset by interest income and dividends of $9.2 million. The increase in expenses compared to expenses incurred in 2023 primarily reflects the company’s business decision to forgive loans extended to the entities acting as general partners and management companies of certain new Helios strategies and certain Helios expenses absorbed by TopCo LP Class B in excess of the management fees received, which represents a realized loss to the company. The decrease in book value per share to $3.84 as of December 31, 2024, as compared to $4.39 as of December 31, 2023 was primarily from the unrealized losses on the company’s investment in TopCo LP. Included in book value per share is $38.3 million of cash and cash equivalents as at December 31, 2024. At December 31, 2024, HFP had 108,179,127 common shares outstanding, as compared to 108,169,817 common shares outstanding at December 31, 2023. HFP's detailed fourth quarter report can be accessed at its website www.heliosinvestment.com/helios-fairfax-partners. About Helios Fairfax Partners Corporation Helios Fairfax Partners Corporation is an investment holding company whose investment objective is to achieve long term capital appreciation, while preserving capital, by investing in public and private equity securities and debt instruments in Africa and African businesses or other businesses with customers, suppliers or business primarily conducted in, or dependent on, Africa. Contact Information Neil WeberLodeRock Advisorsneil.weber@loderockadvisors.com(647) 222-0574         This press release may contain forward-looking statements within the meaning of applicable securities legislation. Forward-looking statements may relate to the company’s or a Portfolio Investment’s future outlook and anticipated events or results and may include statements regarding the financial position, business strategy, growth strategy, budgets, operations, financial results, taxes, dividends, plans and objectives of the company. Particularly, statements regarding future results, performance, achievements, prospects or opportunities of the company, a Portfolio Investment, or the African market are forward-looking statements. In some cases, forward-looking statements can be identified by the use of forward-looking terminology such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate” or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might”, “will” or “will be taken”, “occur” or “be achieved”. Forward-looking statements are based on our opinions and estimates as of the date of this press release and they are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, level of activity, performance or achievements to be materially different from those expressed or implied by such forward-looking statements, including but not limited to the following factors: geopolitical risks; inflation and fluctuating interest rates; tariffs; financial market fluctuations; pace of completing investments; minority investments; reliance on key personnel and risks associated with the Investment Advisory Agreement; concentration risk in Portfolio Investments, including geographic concentration and with respect to Class A and Class B limited partnership interests in the Portfolio Advisor; operating and financial risks of Portfolio Investments; valuation methodologies involve subjective judgments; lawsuits; cybersecurity and technology; reliance on third parties; use of leverage; foreign currency fluctuation; investments may be made in foreign private businesses where information is unreliable or unavailable; significant ownership by Fairfax Financial Holdings Limited (“Fairfax”) and HFP Investments Holdings SARL (“Principal Holdco”) may adversely affect the market price of the subordinate voting shares; emerging markets; South African black economic empowerment; South Africa’s grey-listing; economic risk; climate change, natural disaster, and weather risks; taxation risks; MLI; and trading price of subordinate voting shares relative to book value per share. Additional risks and uncertainties are described in the company’s annual information form dated March 28, 2025 which is available on SEDAR+ at www.sedarplus.ca and on the company’s website at www.heliosinvestment.com/helios-fairfax-partners. These factors and assumptions are not intended to represent a complete list of the factors and assumptions that could affect the company. These factors and assumptions, however, should be considered carefully. Although the company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. The company does not undertake to update any forward-looking statements contained herein, except as required by applicable securities laws. Information on CONSOLIDATED BALANCE SHEETS as at December 31, 2024 and December 31, 2023 (US$ thousands)     December 31, 2024   December 31, 2023           Assets         Cash and cash equivalents   38,320   95,913 Portfolio Investments   394,949   386,002 Total cash and investments   433,269   481,915           Interest receivable   762   412 Income taxes refundable   437   2,874 Other receivables from related parties   126   991 Other assets   1,347   1,167 Property and equipment   1,176   974 Total assets   437,117   488,333           Liabilities         Accounts payable and accrued liabilities   6,594   1,601 Payable to related parties   846   1,096 Lease liability   471   548 Deferred income taxes   13,265   10,492 Total liabilities   21,176   13,737           Equity         Common shareholders’ equity   415,941   474,596     437,117   488,333           Book value per basic share   3.84   4.39           Information on CONSOLIDATED STATEMENTS OF EARNINGS (LOSS) AND COMPREHENSIVE INCOME (LOSS)for the three and twelve months ended December 31, 2024 and 2023 (US$ thousands except per share)   (Unaudited)           Fourth quarter   Year ended December 31,     2024       2023       2024       2023   Income               Interest and dividends   1,964       2,303       9,245       12,036   Net losses on investments   (18,169 )     (68,728 )     (29,164 )     (53,143 ) Net foreign exchange gains (losses)   (1,733 )     816       (305 )     (4,816 )     (17,938 )     (65,609 )     (20,224 )     (45,923 ) Expenses               Investment and advisory fees   729       1,104       4,055       3,492   Loss on loan forgiveness and other expenses   21,979       —       21,979       —   Loss on uncollectible accounts receivable   441       —       441       —   General and administration expenses   4,013       3,522       10,585       12,153   Transaction costs   —       —       1,725       —   Interest expense   463       668       1,799       3,372       27,625       5,294       40,584       19,017                   Earnings (loss) before income taxes   (45,563 )     (70,903 )     (60,808 )     (64,940 ) Provision for (recovery of) income taxes   (3,949 )     9,996       (2,018 )     6,747   Net earnings (loss) and comprehensive income (loss)   (41,614 )     (80,899 )     (58,790 )     (71,687 )                 Net earnings (loss) per share $ (0.38 )   $ (0.75 )   $ (0.54 )   $ (0.66 ) Shares outstanding (weighted average)   108,179,127       108,216,246       108,152,501       108,258,852                                   GLOSSARY OF NON-GAAP AND OTHER FINANCIAL MEASURES Management analyzes and assesses the financial position of the consolidated company in various ways. The measure included in this news release, which has been used consistently and disclosed regularly in the company's Annual Reports and interim financial reporting, does not have a prescribed meaning under IFRS Accounting Standards and may not be comparable to similar measures presented by other companies. This measure is described below. Book value per share - The company considers book value per share a key performance measure in evaluating its objective of long-term capital appreciation, while preserving capital. Book value per share is a key performance measure of the company and is closely monitored. This measure is calculated by the company as common shareholders' equity divided by the number of common shares outstanding. Internal rate of return - The company uses this measure to assess the performance of its investments. This measure represents the annualized rate of return calculated for the company’s portfolio investments, taking into account (i) the timing of cash flows (including cash consideration of purchases, cash proceeds on sales, cumulative interest and dividends received, and return of capital distributions) over the period of the company’s investment, and (ii) the fair value at the end of the reporting period for existing investments. The post Financial Results for the Fourth Quarter of 2024 appeared first on ForexTV.

Read More

Jostens Honors the Los Angeles Dodgers and their Eighth World Series Victory with a Spectacular Ring

Crafted in stunning 14-karat yellow gold with hand-set diamonds and genuine sapphires. 2024 World Series Ring Top & Sides 2024 World Series Ring Top & Sides 2024 World Series Ring Inside 2024 World Series Ring Inside Los Angeles, California, March 28, 2025 (GLOBE NEWSWIRE) -- In collaboration with Jostens, the Los Angeles Dodgers players, coaches, and team leadership received their 2024 World Series Rings in an on-field ceremony at Dodger Stadium. “The 2024 season was nothing short of remarkable for the Dodgers. Following a dominant World Series win, we are honored to be trusted as the Official Championship Ring Partner of the Los Angeles Dodgers,” said Chris Poitras, SVP & GM of Jostens Professional Sports Division. “This stunning ring embodies the Dodgers’ incredible season and World Series title through intricate details and expert craftsmanship.” “We are thrilled by the sparkling design of our new World Series ring,” said Lon Rosen, Executive Vice President & Chief Marketing Officer, Los Angeles Dodgers. “We worked with Jostens to produce a jewel worthy of our memorable 2024 championship run, and they wildly exceeded our expectations. Like our title, we will celebrate this ring for decades to come.” The Los Angeles Dodgers 2024 World Series Ring honors the team’s historic season and 8th title in franchise history through artistic storytelling and impeccable detail. Expertly crafted in 14-karat yellow gold, diamonds and genuine sapphires, this ring celebrates the dedication and determination of their journey to becoming World Champions. The ring top features the iconic LA logo crafted from 17 custom-cut sapphires and surrounded with 47 diamonds. Encircling the logo is a sunburst shape that represents the sunny climate of Los Angeles and features 34 sapphires. On the left and right sides of the ring top are 4 large round diamonds, symbolizing the 8 World Championship titles. An additional 20 diamonds are set along the sides. Adorning the top and bottom of the ring top is the Dodgers 2024 title, WORLD CHAMPIONS, set meticulously with 53 diamonds. A row of 46 diamonds is set along the perimeter of the ring top. Completing the top and bottom edges of the ring are 8 princess-cut sapphires. An additional 108 diamonds cascade from the ring top down the edges of the ring, creating a border around the side panels. Using a specialized hinge mechanism, the top of the ring opens to reveal added storytelling details. Upon opening, Dodger Stadium is displayed in incredible detail and features the Commissioner’s Trophy with 1 diamond, commemorating the 2024 World Series victory. Above, 8 diamonds celebrate the 8 World Championships in Dodgers history. The years 1883 and 2024 are featured, paying tribute to 142 seasons. The left side of the ring top interior features a piece from the bases used in the World Series with the Dodgers City Connect logo in gold. Encircling the base are 34 sapphires honoring the late Dodgers pitcher, Fernando Valenzuela. The left side of the ring features the recipient’s name, symbolic of their contribution to the season. Below, a row of 14 princess-cut sapphires sit atop the iconic Dodger Stadium sign, displaying the player jersey number set in diamonds. Two palm trees make up the background, synonymous with Los Angeles. Completing the left side of the ring is the Major League Baseball logo. The right side of the ring proudly displays the words LOS ANGELES, which pays homage to the home of the Dodgers since 1958. Below, a row of 14 princess-cut sapphires sit atop the championship year date, 2024, set with 29 diamonds. The Dodgers logo is situated among palm trees to complete the right side. The interior of the ring features the LA logo between the championship year date. Below are the logos and series results of the opponents defeated by the Dodgers on their road to become World Series Champions. As a personal touch, players receive their unique signature on the interior palm of the ring. Completing the outer palm is a row of 5 diamonds, representing the 5 runs the Dodgers overcame to win the World Series, an MLB record. In addition to crafting the Los Angeles Dodgers 2020 and 2024 World Series Championship Rings, Jostens has created rings for other Los Angeles champions, including the LA Galaxy 2024 MLS Cup Championship Ring, the Los Angeles FC 2024 U.S. Open Cup Championship Ring, and the Los Angeles Rams 2018 NFC Championship Ring.   THE FAN COLLECTION: Jostens also partnered with the Los Angeles Dodgers to produce an Official World Series Championship Fan Collection allowing Dodger Nation to celebrate the World Series victory. Dodgers fans can capture their piece of the World Series and commemorate this exciting moment in franchise history through a selection of customized jewelry and championship collectibles. All pieces in this collection are inspired by the Dodgers official Championship Ring and are now available for a limited time by ordering online at: www.jostens.com/dodgers. As a part of the World Series Fan Collection, the Dodgers have created a unique purchasing opportunity for fans including a limited-edition ring. Designed to closely replicate the ring awarded to the players, 100 limited-edition rings will be available online at www.jostens.com/dodgers.    ABOUT JOSTENS: Jostens, a trusted partner within the academic and achievement space, provides products and services that help its customers celebrate meaningful milestones. The company's product assortment includes yearbooks, publications, custom-crafted jewelry and consumer goods that serve the K-12, collegiate and professional sports markets. Jostens was founded in 1897 and is headquartered in Minneapolis, Minn. Visit jostens.com for more information. Attachments 2024 World Series Ring Top & Sides 2024 World Series Ring Inside CONTACT: Peter Lai JOSTENS 952-830-3230 Peter.Lai@jostens.com The post Jostens Honors the Los Angeles Dodgers and their Eighth World Series Victory with a Spectacular Ring appeared first on ForexTV.

Read More

Junshi Biosciences Announces 2024 Full Year Financial Results and Provides Corporate Updates

SHANGHAI, March 28, 2025 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced its financial results for the full year of 2024 and provided corporate updates. FINANCIAL HIGHLIGHTS Total revenue of Junshi Biosciences was approximately RMB1,948 million in 2024, representing an increase of approximately 30% compared to 2023, which was mainly due to the increase in revenue from pharmaceutical products, in particular: the domestic sales revenue of our core product, toripalimab, was approximately RMB1,501 million, representing an increase of approximately 66% compared to 2023. Total research and development (“R&D”) expenses of the company were approximately RMB1,275 million in 2024, representing a decrease of approximately 34% compared to 2023. The decrease in R&D expenses was mainly due to the company’s cost control policy and efforts to optimize resource allocation and focus on R&D pipelines with greater potential. In addition, a number of clinical trials of our core product, toripalimab, successively met the primary endpoints, which also contributed to the natural decline of R&D expenditure. Loss attributable to owners of the company decreased to RMB1,282 million in 2024, representing a decrease of approximately RMB999 million or approximately 44% compared to 2023. As of the end of 2024, the company’s aggregate balance of bank balances and cash and financial products was approximately RMB2,917 million, ensuring a relatively sufficient cash position to support the company’s development. BUSINESS HIGHLIGHTS During 2024, our commitment to addressing “unmet medical needs” has driven original, innovative and breakthrough progress in the discovery, R&D and commercialization of innovative therapies and drugs through accelerating international development. Here are the notable achievements and milestones: Advancements in the pipeline: Junshi Biosciences’ innovative R&D field has expanded from monoclonal antibodies to the research and development of various drug modalities, including small molecule drugs, polypeptide drugs, antibody drug conjugates (ADCs), bi-specific or multi-specific antibodies, bispecific antibody drug conjugates, fusion protein and nucleic acid drugs, as well as the exploration of next-generation innovative therapies, including cancer and autoimmune diseases. Our product pipelines cover five major therapeutic areas, including malignant tumors, autoimmune diseases, chronic metabolic diseases, neurologic diseases and infectious diseases. A total of four drugs have been commercialized, around 30 assets are undergoing clinical trials, and over 20 drug candidates are at the preclinical drug development stage. In January 2024, Coherus BioSciences, a partner of Junshi Biosciences, announced that toripalimab was available for access and administration in the United States. Prior to this, toripalimab (US trade name: LOQTORZI®) was approved for marketing by the US Food and Drug Administration (the “FDA”) in October 2023, and is the first drug for the treatment of nasopharyngeal carcinoma (“NPC”) in the United States. At present, it is also the only preferred drug recommended in the National Comprehensive Cancer Network (“NCCN”) Clinical Practice Guidelines in Oncology for Head and Neck Cancers 2025.V1 for the treatment of recurrent/ metastatic NPC across all lines. In January 2024, the new drug application (the “NDA”) for toripalimab for the treatment of NPC was accepted by the Singapore Health Sciences Authority (the “HSA”). In March 2025, the NDA for toripalimab (Singapore trade name: LOQTORZI®) in combination with cisplatin and gemcitabine for the first-line treatment of adult patients with recurrent, not amenable to surgery or radiotherapy, or metastatic NPC has been approved by the HSA. Toripalimab has become the first and only approved immuno-oncology treatment for NPC in Singapore. In April 2024, the Japanese Pharmaceuticals and Medical Devices Agency (the “PMDA”) agreed that the company may proceed with a randomized, double-blind, placebo-controlled, international multi-regional phase 3 clinical study of tifcemalimab (a recombinant humanized anti-BTLA monoclonal antibody, code: TAB004/JS004) in combination with toripalimab as consolidation therapy for patients with limited-stage small cell lung cancer (“LS-SCLC”) without disease progression following chemo-radiotherapy. In April 2024, the supplemental new drug application (the “sNDA”) for toripalimab in combination with axitinib for the first-line treatment for patients with medium to high risk unresectable or metastatic renal cell carcinoma (“RCC”) was approved by the National Medical Products Administration of China (the “NMPA”). This is the first approved immunotherapy for renal carcinoma in China. In April 2024, the NDA for toripalimab in combination with cisplatin and gemcitabine for 1) the first-line treatment of adults with metastatic or recurrent locally advanced NPC and 2) toripalimab, as a single agent, for the treatment of adults with recurrent, unresectable, or metastatic NPC with disease progression on or after platinum-containing chemotherapy was accepted by the Drug Office of the Department of Health, Hong Kong Special Administration Region Government (the “DO”), and was approved by the Pharmacy and Poisons Board of Hong Kong (the “PPB”) in October 2024, making toripalimab the first and only immunotherapy drug for NPC in Hong Kong SAR, China. In June 2024, the primary endpoints of progression-free survival (“PFS”, based on independent radiographic review) and overall survival (“OS”) of a multinational multi-center, randomized, open-label, active controlled phase III clinical study (the HEPATORCH study, NCT04723004) of TUOYI® in combination with bevacizumab for the first-line treatment of advanced hepatocellular carcinoma (“HCC”) met the pre-defined efficacy boundary. The sNDA was accepted by the NMPA in July 2024 and was approved by the NMPA in March 2025. In June 2024, the sNDA for TUOYI® in combination with etoposidein plus platinum as the first-line treatment of extensive-stage small cell lung cancer (“ES-SCLC”) was approved by the NMPA. In June 2024, the sNDA for TUOYI® in combination with paclitaxel for injection (albumin-bound) for the first-line treatment of recurrent or metastatic triple-negative breast cancer (“TNBC”) with a well-validated test to evaluate PD-L1 positive (CPS ≥ 1) was approved by the NMPA. In July 2024, the investigational new drug (“IND”) application for JS125 (a targeted histone deacetylases (“HDACs”) inhibitor) was accepted by the NMPA and approved in September 2024. In July 2024, a positive opinion was obtained from the Committee for Medicinal Products for Human Use (the “CHMP”) of the European Medicines Agency (the “EMA”) for the marketing authorization application (the “MAA”) of toripalimab (European trade name: LOQTORZI®), which recommended approval for the treatment of two indications: toripalimab in combination with cisplatin and gemcitabine for the first-line treatment of adult patients with recurrent, not amenable to surgery or radiotherapy, or metastatic NPC, and toripalimab in combination with cisplatin and paclitaxel for the first-line treatment of adult patients with unresectable advanced, recurrent, or metastatic esophageal squamous cell carcinoma (“ESCC”). In September 2024, this MAA was approved by the European Commission (the “EC”). The approval is applicable to all 27 member states of the European Union (the “EU”), Iceland, Norway and Liechtenstein, making toripalimab the first and only drug for the treatment of NPC and the only first-line treatment for advanced or metastatic ESCC regardless of PD-L1 status in Europe. In August 2024, the sNDA for toripalimab as the first-line treatment for unresectable or metastatic melanoma was accepted by the NMPA. In September 2024 and November 2024, toripalimab was approved for marketing in India and Jordan, respectively, for the treatment of two indications: toripalimab in combination with cisplatin and gemcitabine, for the first-line treatment of adults with metastatic or recurrent, locally advanced NPC and toripalimab, as a single agent, for the treatment of adults with recurrent unresectable or metastatic NPC with disease progression on or after a platinum-containing chemotherapy. Toripalimab officially commenced commercial sales in India in 2024. In October 2024, the NDA for ongericimab injection (a recombinant humanized anti-PCSK9 monoclonal antibody injection, trade name: JUNSHIDA) as the treatment for adult patients with primary hypercholesterolemia (non-familial) and mixed dyslipidemia was approved for marketing by the NMPA. In November 2024, toripalimab (UK trade name: LOQTORZI®) obtained the marketing authorisation from the United Kingdom’s (the “UK”) Medicines and Healthcare products Regulatory Agency (the “MHRA”) for the treatment of two indications: toripalimab in combination with cisplatin and gemcitabine for the first-line treatment of adult patients with recurrent, not amenable to surgery or radiotherapy, or metastatic NPC, and toripalimab in combination with cisplatin and paclitaxel for the first-line treatment of adult patients with unresectable advanced, recurrent, or metastatic ESCC. Toripalimab has become the first and only drug for the treatment of NPC and the only first-line treatment for advanced or metastatic ESCC regardless of PD-L1 status in the UK. In November 2024, four new indications of toripalimab were successfully included in Category B of the National Drug List for Basic Medical Insurance, Work-Related Injury Insurance and Maternity Insurance (Year 2024) (the “NRDL”). The ten approved indications of toripalimab in the Chinese mainland were all included in the NRDL, and TUOYI® is the only anti-PD-1 monoclonal antibody included in the NRDL for the treatment of melanoma, perioperative treatment of non-small cell lung cancer (“NSCLC”), treatment of renal carcinoma and treatment of TNBC. Update on business operations In June 2024, Junshi Biosciences convened the 2023 annual general meeting, the 2024 first class meeting of A shareholders and the 2024 first class meeting of H shareholders, and completed the election of the fourth session of the Board of Directors and the board of supervisors of the company and other matters. In July 2024, Suzhou Union Biopharm Co., Ltd., a wholly-owned subsidiary of Junshi Biosciences, received the CERTIFICATE OF GMP COMPLIANCE OF A MANUFACTURER issued by The Ireland Health Products Regulatory Authority (the “HPRA”) in accordance with the relevant regulations of the EMA. This is the first time that the relevant production facilities of toripalimab obtained the GMP certificate of a member state of the EU. According to the GMP mutual recognition system among the EU member states, obtaining the GMP certificate indicates that the production facilities with the certificate have met the GMP standards of the EU. In August 2024, the A shares of Junshi Biosciences (“A Shares”) were included in the SSE STAR Brand Name Drug Index. The index selects 30 securities of companies listed on the STAR Market with the largest market capitalization and engaged in innovative drugs as constituents, reflecting the overall performance of the securities of the companies listed on the STAR Market and engaged in innovative drugs. As of September 2024, the company completed the implementation of the A-Share repurchase plan, with a total of 815,871 A Shares repurchased, accounting for 0.0828% of the total share capital of the company, which will be used for the purpose of share incentives and/or employee stock ownership plan(s) at an appropriate time in the future. In December 2024, the company’s A Shares were included in the CSI A500 Index. The index selects 500 securities with the largest market capitalization and strong liquidity from various sectors as constituents, reflecting the overall performance of the most representative listed companies across different sectors. About Junshi BiosciencesFounded in December 2012, Junshi Biosciences (HKEX: 1877; SSE: 688180) is an innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of innovative therapeutics. The company has established a diversified R&D pipeline comprising over 50 drug candidates, with five therapeutic focus areas covering cancer, autoimmune, metabolic, neurological, and infectious diseases. Five of the company’s products have received approvals in China and international markets, one of which is toripalimab, China’s first domestically produced and independently developed anti-PD-1 monoclonal antibody. Toripalimab has been approved in over 35 countries and regions including China, the US, and Europe. During the COVID-19 pandemic, Junshi Biosciences actively shouldered the social responsibilities of a Chinese pharmaceutical company through its involvement in developing etesevimab, MINDEWEI®, and other novel therapies for the prevention and treatment of COVID-19. With a mission of “providing patients with world-class, trustworthy, affordable, and innovative drugs,” Junshi Biosciences is “In China, For Global.” At present, the company boasts approximately 2,500 employees in the United States (San Francisco and Maryland) and China (Shanghai, Suzhou, Beijing, Guangzhou, etc.). For more information, please visit: http://www.junshipharma.com. Junshi Biosciences Contact InformationIR Team:Junshi Biosciencesinfo@junshipharma.com+ 86 021-6105 8800 PR Team:Junshi BiosciencesZhi Lizhi_li@junshipharma.com+ 86 021-6105 8800 The post Junshi Biosciences Announces 2024 Full Year Financial Results and Provides Corporate Updates appeared first on ForexTV.

Read More

Turnstone Biologics Corp. Reports Fourth Quarter and Full Year 2024 Financial Results

SAN DIEGO, March 28, 2025 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a biotechnology company historically focused on the development of a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (“Selected TIL”) therapy, today announced its financial results for the fourth quarter and full year ended December 31, 2024, and provided recent corporate updates. Corporate Updates In November 2024, the Company presented preclinical data on its Selected TIL therapies at the 2024 Society for Immunotherapy of Cancer (“SITC”) Annual Meeting. Turnstone also presented clinical data at the SITC TIL Symposium in a presentation titled “TIDAL-01: Enriching for a More Potent TIL Population with Selected TIL Therapy”. In January 2025, Turnstone made the determination to discontinue all TIDAL-01 clinical studies and halted further development of the program. As a result, the Company initiated a process to explore a range of potential strategic alternatives focused on maximizing shareholder value. Turnstone continues to evaluate strategic alternatives and will provide additional updates when it is determined that further disclosure is appropriate or legally required. Financial Highlights Cash, Cash Equivalents and Short-Term Investments: As of December 31, 2024, cash, cash equivalents, and short-term investments were $28.9 million. Research and Development (“R&D”) Expenses: R&D expenses for the three months ended December 31, 2024, were $8.2 million, compared to $13.5 million for the same period in 2023. The decrease was due primarily to corporate restructuring, workforce reduction, and strategic prioritization of pipeline. General and Administrative (“G&A”) Expenses: G&A expenses for the three months ended December 31, 2024, were $3.2 million, compared to $4.4 million for the same period in 2023. The decrease was due primarily to reductions in personnel costs, professional service costs, and other general and administrative costs. Net Loss: Net loss for the three months ended December 31, 2024, was $12.9 million, compared to net loss of $16.5 million for the same period in 2023. About Turnstone Turnstone Biologics is a biotechnology company historically focused on the development of a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (“Selected TIL”) therapy. For additional information about Turnstone, please visit www.turnstonebio.com. Forward-Looking Statements Statements contained in this press release regarding matters that may occur in the future are “forward looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including but not limited to statements in this press release regarding Turnstone’s plans to explore and evaluate a range of potential strategic alternatives focused on maximizing shareholder value. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied by such forward-looking statements. In particular, the following factors, among others, could cause results to differ materially from those expressed or implied by such forward-looking statements: Turnstone’s ability to execute its planned exploration and evaluation of strategic alternatives; and unexpected demands on Turnstone’s cash resources. For a fuller description of risks and uncertainties that could cause actual results to differ from those expressed in forward-looking statements, see Turnstone’s Annual Report on Form 10-K for the year ended December 31, 2024, to be filed with the Securities and Exchange Commission, and Turnstone’s Quarterly Reports on Form 10-Q, especially, in each case, under the caption “Risk Factors,” as well as other documents that may be filed by Turnstone from time to time with the Securities and Exchange Commission. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. Turnstone undertakes no obligation to update any forward-looking statement in this press release, except as required by law. Contact Ahmed AneiziInvestor RelationsTurnstone Biologics(347) 897-5988ahmed.aneizi@turnstonebio.com Condensed Consolidated Statement of Operations and Comprehensive Income (Loss)(unaudited)(In thousands, except share and per share data)               Three Months Ended December 31,   Year Ended December 31,       2024       2023       2024       2023   Collaboration revenue   $ —     $ —     $ —     $ 19,306   Operating expenses:                 Research and development     8,160       13,458       56,104       60,491   General and administrative     3,218       4,398       16,390       17,847   Total operating expenses     11,378       17,856       72,494       78,338   Loss from operations     (11,378 )     (17,856 )     (72,494 )     (59,032 ) Other (expense) income, net     (659 )     1,241       1,694       3,546   Net loss before income taxes     (12,037 )     (16,615 )     (70,800 )     (55,486 ) (Provision) benefit for income taxes     (835 )     165       (37 )     286   Net loss   $ (12,872 )   $ (16,450 )   $ (70,837 )   $ (55,200 ) Other comprehensive (loss) income     (6 )     122       (83 )     294   Total comprehensive loss   $ (12,878 )   $ (16,328 )   $ (70,920 )   $ (54,906 ) Net loss attributable to common stockholders, basic and diluted     (12,872 )     (16,773 )     (70,837 )     (55,239 ) Weighted-average shares of common stock outstanding, basic and diluted     23,059,747       22,934,594       23,037,078       11,562,910   Net loss per share attributable to common stockholders, basic and diluted   $ (0.56 )   $ (0.73 )   $ (3.07 )   $ (4.78 )                   Condensed Consolidated Balance Sheet(unaudited)(In thousands)                 December 31, 2024   December 31, 2023       (unaudited)       Cash and cash equivalents and short term investments   $ 28,926   $ 94,777   Total assets     40,139     112,815   Total liabilities     8,672     14,148   Total stockholders' deficit     31,467     98,667               The post Turnstone Biologics Corp. Reports Fourth Quarter and Full Year 2024 Financial Results appeared first on ForexTV.

Read More

Osisko Development Reports Fourth Quarter and Year-End 2024 Results

(All dollar amounts are expressed in Canadian dollars, unless stated otherwise) MONTREAL, March 28, 2025 (GLOBE NEWSWIRE) -- Osisko Development Corp. (NYSE: ODV, TSXV: ODV) ("Osisko Development" or the "Company") reports its financial and operating results for the three and twelve months ended December 31, 2024 ("Q4 2024"). Q4 2024 HIGHLIGHTS Operating, Financial and Corporate Updates: As of December 31, 2024, the Company had approximately $106.7 million in cash and cash equivalents. Approximately $36.0 million (US$25.0 million) was outstanding as of the end of Q4 2024 under the delayed draw term loan with National Bank of Canada, which matures on October 31, 2025. The Company completed a non-brokered private placement of units pursuant to which it issued an aggregate of 19,163,410 units at a price of US$1.80 per unit for gross proceeds of approximately US$34.5 million (the "2024 Non-Brokered Private Placement"). The 2024 Non-Brokered Private Placement was completed in two tranches comprised of the issuance of (i) 13,426,589 units at a price of US$1.80 per unit for gross proceeds of approximately US$24.2 million, which tranche closed on October 1, 2024, and (ii) 5,736,821 units at a price of US$1.80 per unit for gross proceeds of approximately US$10.3 million, which tranche closed on October 11, 2024. Each unit was comprised of one Common Share and one Common Share purchase warrant of the Company entitling the holder thereof to purchase one Common Share at a price of US$3.00 on or prior to October 1, 2029. On November 12, 2024, the Company completed a brokered private placement pursuant to which it issued an aggregate of 31,946,366 units at a price of US$1.80 per unit for aggregate gross proceeds of approximately US$57.5 million, including the exercise in full of the option granted to the agents (the "2024 Brokered Private Placement"). Each unit was comprised of one Common Share and one Common Share purchase warrant of the Company entitling the holder thereof to purchase one Common Share at a price of US$3.00 on or prior to October 1, 2029. In connection with the 2024 Brokered Private Placement, the agents were paid a cash commission equal to 4.5% of the aggregate gross proceeds. On December 5, 2024, Mr. Stephen Quin was appointed as independent director to the Company's board of directors and, in connection thereof, was subsequently granted 80,000 deferred share units of the Company on December 19, 2024. On December 12, 2024, Ms. Marina Katusa resigned from the Company's board of directors. Cariboo Gold Project – British Columbia, Canada (100%-owned) Fully Permitted Status. On November 20, 2024, the Company was granted permits pursuant to the Mines Act (British Columbia) for its Cariboo Gold Project. Subsequently, on December 12, 2024, the Company was granted permits pursuant to the Environmental Management Act (British Columbia) for the Cariboo Gold Project. Together with the Mines Act (British Columbia) permits, these approvals mark the successful completion of the permitting process for key approvals, solidifying the Cariboo Gold Project's shovel-ready status. The Mines Act (British Columbia) permits grant the Company the ability to proceed with the construction, operation and reclamation activities on each of the sites outlined within the scope of the Project. The Environmental Management Act (British Columbia) permits pertain to any project-related discharges to the environment, including water and air, and the framework and limitations thereof, within the areas outside of the immediate mine site boundaries. Work is ongoing with the Ministry of Water, Land and Resource Stewardship and the Ministry of Forests on obtaining all necessary approvals for the construction of the transmission line. On November 7, 2024, the Company announced that, while it had yet to reach an agreement with the Xatśūll First Nation, it remained committed to ongoing engagement and consultation. Project Financing. The Company is actively engaged in ongoing discussions on various funding options, including a comprehensive project construction financing package, for the development of the Cariboo Gold Project. Pre-Construction Activities. During Q1 2024, under an existing provincial permit, the Company commenced an underground development drift from the existing Cow Portal into the Cariboo Gold Project's Lowhee Zone to extract a bulk sample of up to 10,000 tonnes of mineralized material. 100% of the underground development has been successfully completed, totalling approximately 1,172 m, to access the target area. The extraction, sampling, assaying, and analysis of mineralized material from the target zone is currently ongoing. Approximately 7,400 tonnes of material has been extracted to date. Lengthy timeframes for receipt of assays and analysis of the results have extended completion of the bulk sampling program into Q2 2025. Once all information is available, a reconciliation process to compare the bulk sample results with the predicted tonnes and grade will be undertaken. Optimized Feasibility Study. The Company is in advanced stages of completing an optimized feasibility study ("OFS") for the Cariboo Gold Project. The OFS will incorporate opportunities to enhance and streamline mine development and the process flowsheet, supporting an accelerated development timeline to reach 4,900 tonnes per day throughput earlier than previously contemplated. It will also reflect updated metal price and foreign exchange assumptions. Additionally, the OFS will integrate updated operating and capital cost estimates, while considering ways to reduce and mitigate any potential capital and operating cost pressures. The OFS base case will remain aligned with the existing permitting framework.     Figure 1: Cariboo Gold Project – Permitting Timeline Summary Tintic Project – Utah, U.S.A. (100%-owned) Phase I Regional Drilling. In 2024, the Company completed two surface diamond drill holes totalling approximately 2,920 m (9,581 ft) at the Big Hill target area testing for copper-gold-molybdenum porphyry mineralization potential. Based on the geological information from these drill holes, the Company identified several high-priority targets for a next phase of the porphyry exploration program. Phase II Regional Drilling. As part of the ongoing Phase II regional drilling program initiated in December 2024, the Company is advancing the completion of two drill holes on the Big Hill West and Zuma porphyry targets, expected to be completed in the coming months. San Antonio Gold Project – Sonora State, Mexico (100%-owned) The San Antonio Gold Project remains in care and maintenance. The Company is awaiting further guidance from the Mexican government regarding the permitting process and the status of open-pit mining in the country. The Company continues to conduct a strategic review of the project and engaged a financial advisor in connection thereof. The strategic review includes, among others, exploring the potential for a financial or strategic partner in the asset or a full or partial sale of the asset. KEY UPCOMING MILESTONES Key Project Milestones   Expected Timing  of Completion   Anticipated  Remaining Costs* Cariboo Gold Project(1)         Permitting   Completed – Q4 2024   $nil Electrical and Communication   Q1 2025   $0.7 million Bulk Sample   Q2 2025   $6.4 million CGP Underground Development   Q2 2025   $8.7 million Updated CGP Feasibility   Q2 2025   $2.5 million Environmental, other pre-construction work & roadheader   Q2 2025   $7.2 million Water and Waste Management   Q4 2025   $7.5 million Tintic Project         Regional Drilling – Phase I   Completed – Q2 2024   $nil Regional Drilling – Phase II   Q2 2025   $5.0 million           *as at December 31, 2024 Notes: (1)   The expenditures disclosed in this table include amounts approved by the Board of Directors up until the end of June 2025. Additional expenditures will be required to complete certain of the milestones and are subject to approval by the Board of Directors. SUBSEQUENT TO Q4 2024 On January 9, 2025, the Company announced that Mr. David Rouleau was appointed as Vice President, Project Development, and Mr. Éric Tremblay resigned from his position as Chief Operating Officer of the Company. On February 3, 2025, the Company released drilling results from its 2024 initial exploration and historic data validation infill drill campaign at its Quesnel River Mine Prospect located within the Company's wider Cariboo Gold Project. On March 26, 2025, the Company appointed Philip Rabenok as Vice President, Investor Relations. Mr. Rabenok joined Osisko Development in November 2022 as Director, Investor Relations. 2024 Year-End Disclosure Documents The Company's annual information form ("AIF") for the year ended December 31, 2024, audited consolidated financial statements (the "Financial Statements") and related management's discussion and analysis ("MD&A") for the three and twelve months ended December 31, 2024 have been filed with Canadian securities regulatory authorities. Osisko Development has also filed its Annual Report Form 40-F consisting of its AIF, Financial Statements and MD&A for the year ended December 31, 2024 with the U.S. Securities and Exchange Commission. These filings are available on the Company's website at www.osiskodev.com, on SEDAR+ (www.sedarplus.ca) and on EDGAR (www.sec.gov) under Osisko Development's issuer profile. Hard copies of these documents will be provided to shareholders of the Company upon written request to the Company's Investor Relations department, 1100, Av. des Canadiens-de-Montreal, Suite 300, Montreal, Quebec, Canada H3B 2S2 or to ir@osiskodev.com. Qualified Persons The scientific and technical information contained in this news release has been reviewed and approved by Daniel Downton, P.Geo., Chief Resource Geologist of Osisko Development, a "qualified person" within the meaning of National Instrument 43-101 – Standards of Disclosure for Mineral Projects ("NI 43-101"). Technical Reports Information relating to the Cariboo Gold Project and the current feasibility on the Cariboo Gold Project is supported by the technical report titled "Feasibility Study for the Cariboo Gold Project, District of Well, British Columbia, Canada", dated January 10, 2023 (amended January 12, 2023) with an effective date of December 30, 2022 (the "Cariboo Technical Report"). Information relating to the Tintic Project and the current mineral resource estimate for the Trixie deposit (the "2024 Trixie MRE") is supported by the technical report titled "NI 43-101 Technical Report, Mineral Resource Estimate for the Trixie Deposit, Tintic Project, Utah, United States of America" dated April 25, 2024 (with an effective date of March 14, 2024) (the "Tintic Technical Report"). Information relating to San Antonio Gold Project is supported by the technical report titled "NI 43-101 Technical Report for the 2022 Mineral Resource Estimate on the San Antonio Project, Sonora, Mexico", dated July 12, 2022 (with an effective date of June 24, 2022) (the "San Antonio Technical Report", collectively, with the Tintic Technical Report and the Cariboo Technical Report, the "Technical Reports"). For readers to fully understand the information in the Technical Reports, reference should be made to the full text of the Technical Reports in their entirety, including all assumptions, qualifications and limitations thereof. The Technical Reports are intended to be read as a whole, and sections should not be read or relied upon out of context. The Technical Reports were prepared in accordance with NI 43-101 and are available electronically on SEDAR+ (www.sedarplus.ca) and on EDGAR (www.sec.gov) under Osisko Development's issuer profile and on the Company's website at www.osiskodev.com.    End Notes (excluding tables) 1.     In this news release the Company uses certain abbreviations, including: meters ("m"); feet ("ft").   ABOUT OSISKO DEVELOPMENT CORP. Osisko Development Corp. is a North American gold development company focused on past-producing mining camps located in mining friendly jurisdictions with district scale potential. The Company's objective is to become an intermediate gold producer by advancing its flagship fully permitted 100%-owned Cariboo Gold Project, located in central B.C., Canada. Its project pipeline is complemented by the Tintic Project in the historic East Tintic mining district in Utah, U.S.A., and the San Antonio Gold Project in Sonora, Mexico—brownfield properties with significant exploration potential, extensive historical mining data, access to existing infrastructure and skilled labour. The Company's strategy is to develop attractive, long-life, socially and environmentally responsible mining assets, while minimizing exposure to development risk and growing mineral resources. For further information, visit our website at www.osiskodev.com or contact: Sean Roosen Philip Rabenok Chairman and CEO Vice President, Investor Relations Email: sroosen@osiskodev.com Email: prabenok@osiskodev.com Tel: +1 (514) 940-0685 Tel: +1 (437) 423-3644 CAUTIONARY STATEMENTS Cautionary Statement Regarding Estimates of Mineral Resources This news release uses the terms measured, indicated and inferred mineral resources as a relative measure of the level of confidence in the resource estimate. Readers are cautioned that mineral resources are not mineral reserves and that the economic viability of resources that are not mineral reserves has not been demonstrated. The mineral resource estimate disclosed in this news release may be materially affected by geology, environmental, permitting, legal, title, socio-political, marketing or other relevant issues. The mineral resource estimate is classified in accordance with the Canadian Institute of Mining, Metallurgy and Petroleum's "CIM Definition Standards on Mineral Resources and Mineral Reserves" incorporated by reference into NI 43-101. Under NI 43-101, estimates of inferred mineral resources may not form the basis of feasibility or pre-feasibility studies or economic studies except for preliminary economic assessments. Readers are cautioned not to assume that further work on the stated resources will lead to mineral reserves that can be mined economically. Cautionary Statement Regarding Financing Risks The Company's development and exploration activities are subject to financing risks. At the present time, the Company has exploration and development assets which may generate periodic revenues through test mining, but has no mines in the commercial production stage that generate positive cash flows. The Company cautions that test mining at its operations could be suspended at any time. The Company's ability to explore for and discover potential economic projects, and then to bring them into production, is highly dependent upon its ability to raise equity and debt capital in the financial markets. Any projects that the Company develops will require significant capital expenditures. To obtain such funds, the Company may sell additional securities including, but not limited to, the Company's shares or some form of convertible security, the effect of which may result in a substantial dilution of the equity interests of the Company's Shareholders. Alternatively, the Company may also sell a part of its interest in an asset in order to raise capital. There is no assurance that the Company will be able to raise the funds required to continue its exploration programs and finance the development of any potentially economic deposit that is identified on acceptable terms or at all. The failure to obtain the necessary financing(s) could have a material adverse effect on the Company's growth strategy, results of operations, financial condition and project scheduling. Cautionary Statement Regarding Test Mining Without Feasibility Study The Company cautions that its prior decision to commence small-scale underground mining activities and batch vat leaching at the Trixie test mine was made without the benefit of a feasibility study, or reported mineral resources or mineral reserves, demonstrating economic and technical viability, and, as a result there may be increased uncertainty of achieving any particular level of recovery of material or the cost of such recovery. The Company cautions that historically, such projects have a much higher risk of economic and technical failure. Small scale test-mining at Trixie was suspended in December 2022, resumed in the second quarter of 2023, and suspended once again in December 2023. If and when small-scale test-mining recommences at Trixie, there is no guarantee that production will continue as anticipated or at all or that anticipated production costs will be achieved. The failure to continue production may have a material adverse impact on the Company's ability to generate revenue and cash flow to fund operations. Failure to achieve the anticipated production costs may have a material adverse impact on the Company's cash flow and potential profitability. In continuing operations at Trixie after closing, the Company has not based its decision to continue such operations on a feasibility study, or reported mineral resources or mineral reserves demonstrating economic and technical viability. Cautionary Statement to U.S. Investors The Company is subject to the reporting requirements of the applicable Canadian securities laws and as a result reports information regarding mineral properties, mineralization and estimates of mineral reserves and mineral resources, including the information in its technical reports, financial statements, MD&A and this news release, in accordance with Canadian reporting requirements, which are governed by NI 43-101. As such, such information concerning mineral properties, mineralization and estimates of mineral reserves and mineral resources, including the information in its technical reports, financial statements, MD&A and this news release, is not comparable to similar information made public by U.S. companies subject to the reporting and disclosure requirements of the U.S. Securities and Exchange Commission ("SEC"). CAUTION REGARDING FORWARD LOOKING STATEMENTS Certain statements contained in this news release may be deemed "forward-looking statements" within the meaning of the United States Private Securities Litigation Reform Act of 1995 and "forward-looking information" within the meaning of applicable Canadian securities legislation (together, "forward-looking statements"). These forward-looking statements, by their nature, require Osisko Development to make certain assumptions and necessarily involve known and unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied in these forward-looking statements. Forward-looking statements are not guarantees of performance. Words such as "may", "will", "would", "could", "expect", "believe", "plan", "anticipate", "intend", "estimate", "continue", or the negative or comparable terminology, as well as terms usually used in the future and the conditional, are intended to identify forward-looking statements. Information contained in forward-looking statements is based upon certain material assumptions that were applied in drawing a conclusion or making a forecast or projection, including the assumptions, qualifications and limitations relating to the Cariboo Gold Project being fully permitted and shovel ready; the ability of the Company to obtain project finance for the development of the Cariboo Gold Project; proposed pre-construction activities; the results of the OFS, including assumptions relating to updated metal prices and foreign exchange assumptions; Phase I and II regional drilling at Tintic and related priority targets; the long-term prospects of San Antonio, including the permitting process, status on care and maintenance and status of the strategic review; the significance of target drilling; the ability of the Company to complete a follow-up targeted geophysical survey and the exploration success thereof (if any); the potential impact of tariffs and other trade restrictions (if any); the Company being construction and operation ready; unlocking Cariboo's potential for shareholders, Indigenous nations and other stakeholders; the ability of the Company to complete the optimized feasibility study and the scope, results and timing of thereof; progress and timing in respect of pre-construction activities at Cariboo including bulk sample and underground development work; category conversion; the timing and status of permitting; the future development and operations at the Cariboo Gold Project; the results of ongoing stakeholder engagement; the capital resources available to the Company; the ability of the Company to execute its planned activities, including as a result of its ability to seek additional funding or to reduce planned expenditures; the ability of the Company to obtain future financing and the terms of such financing including a fully-funded solution for the Cariboo Gold Project; management's perceptions of historical trends, current conditions and expected future developments; the utility and significance of historic data, including the significance of the district hosting past producing mines; future mining activities; the potential of high grade gold mineralization on Trixie and Cariboo; the ability and timing for Cariboo to reach commercial production (if at all); sustainability and environmental impacts of operations at the Company's properties; the results (if any) of further exploration work to define and expand mineral resources; the ability of exploration work (including drilling) to accurately predict mineralization; the ability to generate additional drill targets; the ability of management to understand the geology and potential of the Company's properties; the ability of the Company to expand mineral resources beyond current mineral resource estimates; the ability of the Company to complete its exploration and development objectives for its projects in the timing contemplated and within expected costs (if at all); the ongoing advancement of the deposits on the Company's properties; the impact of permitting delays at San Antonio Gold Project; the outcome of the strategic review of the San Antonio Gold Project; sustainability and environmental impacts of operations at the Company's properties; the ability and timing for Cariboo to reach commercial production (if at all); the ability to adapt to changes in gold prices, estimates of costs, estimates of planned exploration and development expenditures; the ability of the Company to obtain further capital on reasonable terms; the profitability (if at all) of the Company's operations; as well as other considerations that are believed to be appropriate in the circumstances, and any other information herein that is not a historical fact may be "forward looking information". Material assumptions also include, management's perceptions of historical trends, management's understanding of the permitting process and status thereof, the ability of exploration (including drilling and chip sampling assays, and face sampling) to accurately predict mineralization, budget constraints and access to capital on terms acceptable to the Company, current conditions and expected future developments, regulatory framework remaining defined and understood, results of further exploration work to define or expand any mineral resources, as well as other considerations that are believed to be appropriate in the circumstances. Osisko Development considers its assumptions to be reasonable based on information currently available, but cautions the reader that their assumptions regarding future events, many of which are beyond the control of Osisko Development, may ultimately prove to be incorrect since they are subject to risks and uncertainties that affect Osisko Development and its business. Such risks and uncertainties include, among others, risks relating to third-party approvals, including the issuance of permits by the government, capital market conditions and the Company's ability to access capital on terms acceptable to the Company for the contemplated exploration and development at the Company's properties; the ability to continue current operations and exploration; regulatory framework and presence of laws and regulations that may impose restrictions on mining; the ability of exploration activities (including drill results and chip sampling, and face sampling results) to accurately predict mineralization; errors in management's geological modelling; the ability to expand operations or complete further exploration activities; the timing and ability of the Company to obtain required approvals and permits; the results of exploration activities; risks relating to exploration, development and mining activities; the global economic climate; metal and commodity prices; fluctuations in the currency markets; dilution; environmental risks; and community, non-governmental and governmental actions and the impact of stakeholder actions. Osisko Development is confident a robust consultation process was followed in relation to its received BC Mines Act and Environmental Management Act permits for the Cariboo Gold Project and continues to actively consult and engage with Indigenous nations and stakeholders. While any party may seek to have the decision related to the BC Mines Act and/or Environmental Management Act permits reviewed by the courts, the Company does not expect that such a review will impact its ability to proceed with the construction and operation of the Cariboo Gold Project in accordance with the approved BC Mines Act and Environmental Management Act permits. Readers are urged to consult the disclosure provided under the heading "Risk Factors" in the Company's annual information form for the year ended December 31, 2024 as well as the financial statements and MD&A for the year ended December 31, 2024, which have been filed on SEDAR+ (www.sedarplus.ca) under Osisko Development's issuer profile and on the SEC's EDGAR website (www.sec.gov), for further information regarding the risks and other factors facing the Company, its business and operations. Although the Company's believes the expectations conveyed by the forward-looking statements are reasonable based on information available as of the date hereof, no assurances can be given as to future results, levels of activity and achievements. The Company disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or results or otherwise, except as required by law. Forward-looking statements are not guarantees of performance and there can be no assurance that these forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release. No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein. A figure accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/e1a6c8e8-a44c-491b-9470-66cb93b45ddc The post Osisko Development Reports Fourth Quarter and Year-End 2024 Results appeared first on ForexTV.

Read More

Partners Value Split Corp. Announces 2024 Annual Results

TORONTO, March 28, 2025 (GLOBE NEWSWIRE) -- Partners Value Split Corp. (the “Company”, TSX: PVS.PR.G, PVS.PR.H, PVS.PR.I, PVS.PR.J, PVS.PR.K, PVS.PR.L) announced today that the net asset value per unit was $171.41 at December 31, 2024 (December 31, 2023 – $124.10). All amounts are in U.S. dollars. Income available for distribution for the year ended December 31, 2024, was $85 million, compared to $73 million in the prior year. The increase in income was primarily attributable to the increase in dividend rate per share by Brookfield Corporation (the “Corporation”) and Brookfield Asset Management Ltd. (the “Manager”). During the year ended December 31, 2024, the Company declared and paid dividends in the amount of $79 million (December 31, 2023 – $50 million) to the holders of its capital shares. The net comprehensive income for the year ended December 31, 2024, of $2.6 billion was primarily driven by unrealized mark-to-market movement on the share prices of the Corporation and the Manager shares. The Corporation share price was $57.45 as at December 31, 2024 (December 31, 2023 – $40.12) and the Manager share price was $54.19 as at December 31, 2024 (December 31, 2023 – $40.17). The Company’s capital shares, and preferred shares are referred to collectively as units, with each unit consisting of one capital share and one preferred share (“unit”). The net asset value per unit is posted monthly on our website at www.partnersvaluesplit.com. STATEMENTS OF COMPREHENSIVE INCOME For the years ended December 31(Thousands of US dollars, except per unit amounts)     2024       2023   Income             Dividend income   $ 83,728     $ 71,767   Other investment income     1,265       1,817         84,993       73,584   Expenses             Management fees     (18)       (19)   Audit fees     (25)       (21)   Administrative and other     (327)       (278)         (370)       (318)   Income available for distribution     84,623       73,266   Distributions paid on senior preferred shares and debentures     (31,011)       (31,859)   Income available for distribution to junior preferred and capital shares     53,612       41,407   Change in unrealized and realized value of investment     2,491,751       1,379,718   Amortization of share issuance costs     (3,211)       (3,233)   Unrealized foreign exchange gain (loss)     72,344       (19,872)   Net comprehensive income   $ 2,614,496     $ 1,398,020   Comprehensive income per unit   $ 53.64     $ 28.71   Quarterly distribution rate per senior preferred share (C$)                 –         Class AA, Series 9     0.3063       0.3063   –         Class AA, Series 10     0.2938       0.2938   –         Class AA, Series 11     0.2969       0.2969   –         Class AA, Series 12     0.2750       0.2750   –         Class AA, Series 13     0.2781       0.2781   –         Class AA, Series 14     0.3438       N/A As at December 31, 2024, the Company owned 120 million Class A Limited Voting shares of the Corporation, and 30 million Class A Limited Voting Shares of the Manager, which together generate cash flow through dividend payments that fund quarterly fixed cumulative preferential dividends for the holders of the Company’s preferred shares and provide the holders of the Company's capital shares the opportunity to participate in any capital appreciation of the Brookfield shares. Brookfield Corporation is a leading global investment firm focused on building long‐term wealth for institutions and individuals around the world. This capital is allocated across three core businesses: asset management, wealth solutions and operating businesses. The Corporation is listed on the New York and Toronto Stock Exchanges under the symbol BN and BN.TO respectively. The Company’s investment in Corporation represents approximately an 8% interest in the Corporation. Brookfield Asset Management Ltd. is a leading global alternative asset manager with over $1 trillion of assets under management across real estate, infrastructure, renewable power and transition, private equity and credit as of December 31, 2024. The Manager is listed on the New York and Toronto Stock Exchanges under the symbol BAM and BAM.TO respectively. The Company’s investment in Manager represents approximately a 7% interest in the Manager. For further information, contact Investor Relations at 416-643-7621. Note: This news release contains “forward-looking information” within the meaning of Canadian provincial securities laws and regulations. The words “generate” and “enable” and other expressions which are predictions of or indicate future events, trends or prospects and which do not relate to historical matters identify forward-looking information. Forward-looking information in this news release includes statements with regard to the generation of cumulative preferential dividends for the holders of the Company’s preferred shares and potential participation by the holders of the Company’s capital shares in the capital appreciation of Brookfield Shares. Although the Company believes that the anticipated future results or achievements expressed or implied by the forward-looking information and statements are based upon reasonable assumptions and expectations, the reader should not place undue reliance on the forward-looking information and statements because they involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to differ materially from anticipated future results, performance or achievement expressed or implied by such forward-looking information and statements. Factors that could cause actual results to differ materially from those contemplated or implied by forward‐looking statements and information include, but are not limited to: the financial performance of Brookfield Corporation, the impact or unanticipated impact of general economic, political and market factors; the behavior of financial markets, including fluctuations in interest and foreign exchanges rates; limitations on the liquidity of our investments; global equity and capital markets and the availability of equity and debt financing and refinancing within these markets; strategic actions including dispositions; changes in accounting policies and methods used to report financial condition (including uncertainties associated with critical accounting assumptions and estimates); the effect of applying future accounting changes; business competition; operational and reputational risks; technological change; changes in government regulation and legislation; changes in tax laws; risks associated with the use of financial leverage; catastrophic events, such as earthquakes and hurricanes; the possible impact of international conflicts and other developments including terrorist acts; and other risks and factors detailed from time to time in the Company’s documents filed with the securities regulators in Canada. We caution that the foregoing list of important factors that may affect future results is not exhaustive. When relying on our forward-looking information to make decisions with respect to the Company, investors and others should carefully consider the foregoing factors and other uncertainties and potential events. Except as may be required by law, the Company undertakes no obligation to publicly update or revise any forward-looking information or statements, whether written or oral, that may be as a result of new information, future events or otherwise. Reference should be made to the Company’s most recent Annual Information Form for a description of the major risk factors. The post Partners Value Split Corp. Announces 2024 Annual Results appeared first on ForexTV.

Read More

Partners Value Investments L.P. Announces 2024 Annual Results

TORONTO, March 28, 2025 (GLOBE NEWSWIRE) -- Partners Value Investments L.P. (the “Partnership”, TSX: PVF.UN TSX:PVF.PR.U) announced today its financial results for the year ended December 31, 2024. All amounts are stated in U.S. dollars. The Partnership recorded net income of $74 million for the year ended December 31, 2024, compared to $15 million in the prior year. The increase in income was primarily driven by higher investment income and valuation gains as well as foreign currency gains. Income of $65 million was attributable to the Equity Limited Partners, and $9 million was attributable to Preferred Limited Partners. As at December 31, 2024, the market prices of a Brookfield Corporation (the “Corporation”, NYSE/TSX: BN) and Brookfield Asset Management Ltd. (the “Manager”, NYSE/TSX: BAM) share were $57.45 and $54.19, respectively. As at March 28, 2025, the market prices of a BN and BAM share were $51.85 and $48.50, respectively. Consolidated Statements of Operations For the years ended December 31       (Thousands, US dollars)       2024       2023   Investment income               Dividends     $ 95,071     $ 85,114   Other investment income       18,609       11,802           113,680       96,916   Expenses               Operating expenses       (6,552 )     (6,156 ) Financing costs       (10,136 )     (9,484 ) Retractable preferred share dividends       (39,879 )     (41,954 )         (56,567 )     (57,594 )                 Other items               Investment valuation gains (losses)       5,703       (6,237 ) Amortization of deferred financing costs       (3,506 )     (3,380 ) Foreign currency gains (losses)       25,519       (10,435 ) Current taxes expense       (3,514 )     (1,270 ) Deferred taxes expense       (7,489 )     (3,280 ) Net income     $ 73,826     $ 14,720     The information in the following table shows the changes in net book value: For the years ended December 31 2024   2023 (Thousands, except per unit amounts)   Total        Per Unit      Total       Per Unit Net book value, beginning of year1 $ 5,783,620     $ 70.74   $ 4,656,824     $ 57.60 Net income2   65,054             5,368         Other comprehensive income2   2,690,274             1,443,806         Adjustment for impact of warrants1   (148,510 )           (89,755 )       Re-organization3   —             98,318         Distribution3   —             (327,850 )       Equity LP repurchases   (14,756 )           (3,091 )       Net book value, end of year4 $ 8,375,682     $ 102.80   $ 5,783,620     $ 70.74 Calculated on a fully diluted basis. Net book value is a non‐IFRS measure used by management to measure the value of an Equity Limited Partnership (“Equity LP”) unit on a fully diluted basis. It is equal to total equity less General Partner equity, Preferred Limited Partners’ equity, non-controlling interests’ equity plus the value of consideration to be received on exercising of warrants, which as at December 31, 2024, was $114 million (December 31, 2023 – $263 million). Attributable to Equity Limited Partners. As a result of the 2023 re-organization, the Partnership issued net equity of $98 million and a distribution-in-kind of $328 million of net assets to Equity Limited Partners. At the end of the year, the diluted Equity LP units outstanding were 81,474,610 (December 31, 2023 – 81,760,920); this includes 5,640,600 (December 31, 2023 – nil) Equity LP units exchangeable on a one-for-one basis with shares held by a non-wholly owned subsidiary, and units issued through the exercise of all outstanding warrants; including 585,938 (December 31, 2023 – 26,085,938) warrants held by partially-owned subsidiaries of the Partnership. Financial Profile The Partnership’s principal investments are its interest in approximately 121 million Class A Limited Voting Shares of the Corporation and approximately 31 million Class A Limited Voting Shares of the Manager. This represents approximately an 8% interest in the Corporation and a 7% interest in the Manager as at December 31, 2024. In addition, the Partnership owns a diversified investment portfolio of marketable securities and private fund interests. The information in the following table has been extracted from the Partnership’s Consolidated Statements of Financial Position: Consolidated Statements of Financial Position As at (Thousands, US dollars)     December 31, 2024       December 31, 2023 Assets               Cash and cash equivalents   $ 156,977     $ 199,856 Accounts receivable and other assets     48,924       31,416 Deferred tax asset     —       4,309 Investment in Brookfield Corporation1     6,949,656       4,853,261 Investment in Brookfield Asset Management Ltd.2     1,669,488       1,237,554 Other investments carried at fair value     814,877       612,009     $ 9,639,922     $ 6,938,405 Liabilities and equity               Accounts payable and other liabilities   $ 42,055     $ 34,150 Corporate borrowings     208,168       225,789 Preferred shares3     939,057       993,267 Deferred tax liability     7,933       —       1,197,213       1,253,206 Equity               Equity Limited Partners     8,261,639       5,521,067 General Partner4     —       — Preferred Limited Partners     152,040       152,152 Non-controlling interests     29,030       11,980       8,442,709       5,685,199     $ 9,639,922     $ 6,938,405 The investment in the Corporation consists of 121 million Corporation shares with a quoted market value of $57.45 per share as at December 31, 2024 (December 31, 2023 – $40.12). The investment in the Manager consists of 31 million Manager shares with a quoted market value of $54.19 per share as at December 31, 2024 (December 31, 2023 – $40.17). Represents $712 million of retractable preferred shares less $9 million of unamortized issue costs as at December 31, 2024(December 31, 2023 – $767 million less $10 million) and $236 million of three series of preferred shares (December 31, 2023 – $236 million). In connection with the 2023 re‐organization of Partners Value Investments LP on November 24, 2023, the General Partner’s interest was reduced to $1 from $1 thousand in the prior year. For further information, contact Investor Relations at ir@pvii.ca or 416-643-7621. Note: This news release contains “forward-looking information” within the meaning of Canadian provincial securities laws and “forward-looking statements” within the meaning of applicable Canadian securities regulations. The words “potential” and “estimated” and other expressions which are predictions of or indicate future events, trends or prospects and which do not relate to historical matters, identify forward-looking information. Although the Partnership believes that its anticipated future results, performance or achievements expressed or implied by the forward-looking statements and information are based upon reasonable assumptions and expectations, the reader should not place undue reliance on forward-looking statements and information because they involve known and unknown risks, uncertainties and other factors, many of which are beyond its control, which may cause the actual results, performance or achievements of the Partnership to differ materially from anticipated future results, performance or achievement expressed or implied by such forward-looking statements and information. Factors that could cause actual results to differ materially from those contemplated or implied by forward‐looking statements and information include, but are not limited to: the financial performance of Brookfield Corporation, the impact or unanticipated impact of general economic, political and market factors; the behavior of financial markets, including fluctuations in interest and foreign exchanges rates; limitations on the liquidity of our investments; global equity and capital markets and the availability of equity and debt financing and refinancing within these markets; strategic actions including dispositions; changes in accounting policies and methods used to report financial condition (including uncertainties associated with critical accounting assumptions and estimates); the effect of applying future accounting changes; business competition; operational and reputational risks; technological change; changes in government regulation and legislation; changes in tax laws; risks associated with the use of financial leverage; catastrophic events, such as earthquakes and hurricanes; the possible impact of international conflicts and other developments including terrorist acts; and other risks and factors detailed from time to time in the Partnership’s documents filed with the securities regulators in Canada. The Partnership cautions that the foregoing list of important factors that may affect future results is not exhaustive. When relying on the Partnership’s forward-looking statements and information, investors and others should carefully consider the foregoing factors and other uncertainties and potential events. Except as required by law, the Partnership undertakes no obligation to publicly update or revise any forward-looking statements and information, whether written or oral, that may be as a result of new information, future events or otherwise. The post Partners Value Investments L.P. Announces 2024 Annual Results appeared first on ForexTV.

Read More

Partners Value Investments Inc. Announces 2024 Annual Results

TORONTO, March 28, 2025 (GLOBE NEWSWIRE) -- Partners Value Investments Inc. (the “Company”, TSX: PVF.WT, PVF.PR.V) announced today its financial results for the year ended December 31, 2024. All amounts are stated in U.S. dollars. The Company recorded net loss of $3.8 billion for the year ended December 31, 2024, compared to $333 million in the prior year. The decrease in income was primarily attributable to the current year remeasurement losses associated with the retractable shares and warrant liabilities, partially offset by higher investment income and valuation gains as well as foreign currency gains compared to the prior year. The Company’s retractable common shares are classified as liabilities due to their cash retraction feature. The remeasurement gains or losses in a given period are driven by the respective appreciation or depreciation of the Partners Value Investments L.P. (the “Partnership”) unit price as the exchangeable shares are recognized at fair value based on the quoted price of the Partnership’s Equity LP units. During the year, the Partnership unit price increased by $51.79 compared to $4.96 in the prior year. Excluding retractable share and warrant liability remeasurement gains and dividends paid on retractable shares, Adjusted Earnings for the Company was $122 million for the year ended December 31, 2024, compared to $27 million in the prior year. Adjusted Earnings were higher in the current year as a result of higher investment income and valuation gains as well as foreign currency gains. As at December 31, 2024, the market prices of a Brookfield Corporation (the “Corporation”, NYSE/TSX: BN) and Brookfield Asset Management Ltd. (the “Manager”, NYSE/TSX: BAM) share were $57.45 and $54.19, respectively. As at March 28, 2025, the market prices of a BN and BAM share were $51.85 and $48.50, respectively. Consolidated Statements of Operations For the years ended December 31(Thousands, US dollars)                   2024       2023     Investment income                       Dividends           $ 108,428     $ 96,269     Other investment income             18,607       11,802                   127,035       108,071     Expenses                       Operating expenses             (5,553 )     (5,843 )   Financing costs             (38,777 )     (35,210 )   Retractable preferred share dividends             (33,399 )     (35,456 )                 (77,729 )     (76,509 )   Other items                       Investment valuation gains (losses)             5,703       (6,237 )   Retractable share remeasurement losses             (3,575,080 )     (281,451 )   Warrant liability remeasurement losses             (306,473 )     (52,694 )   Amortization of deferred financing costs             (3,506 )     (3,380 )   Foreign currency gain (loss)             53,280       (15,983 )   Current tax expense             (3,514 )     (1,270 )   Deferred tax expense             (7,489 )     (3,280 )   Net loss           $ (3,787,773 )   $ (332,733 )   Financial Profile The Company’s principal investments are its interest in 121 million Class A Limited Voting Shares of the Corporation and approximately 31 million Class A Limited Voting Shares of the Manager. This represents approximately an 8% interest in the Corporation and a 7% interest in the Manager as at December 31, 2024. In addition, the Company owns a diversified investment portfolio of marketable securities and private fund interests. The information in the following table has been extracted from the Company’s Consolidated Statements of Financial Position: Consolidated Statements of Financial Position As at(Thousands, US dollars)       December 31, 2024       December 31, 2023   Assets               Cash and cash equivalents     $ 156,952     $ 199,856   Accounts receivable and other assets       69,776       31,456   Deferred tax assets       —       4,309   Investment in Brookfield Corporation1       6,949,656       4,853,261   Investment in Brookfield Asset Management Ltd.2       1,669,488       1,237,554   Other investments carried at fair value       1,141,048       889,398         $ 9,986,920     $ 7,215,834   Liabilities and Equity               Accounts payable and other liabilities     $ 42,824     $ 34,916   Corporate borrowings       208,168       225,789   Preferred shares3       703,044       757,254   Retractable common shares       7,312,467       3,718,510   Warrant liability       494,710       218,051   Deferred tax liabilities       7,933       —           8,769,146       4,954,520   Equity               Accumulated deficit       (6,821,786 )     (3,034,013 ) Accumulated other comprehensive income       8,027,580       5,283,347   Non-controlling interest       11,980       11,980         $ 9,986,920     $ 7,215,834   The investment in Brookfield Corporation consists of 121 million Corporation shares with a quoted market value of $57.45 per share as at December 31, 2024 (December 31, 2023 – $40.12). The investment in Brookfield Asset Management Ltd. consists of 31 million Manager shares with a quoted market value of $54.19 per share as at December 31, 2024 (December 31, 2023 – $40.17). Represents $712 million of retractable preferred shares less $9 million of unamortized issue costs as at December 31, 2024 (December 31, 2023 – $767 million less $10 million). For further information, contact Investor Relations at ir@pvii.ca or 416-643-7621. Note: This news release contains “forward-looking information” within the meaning of Canadian provincial securities laws and “forward-looking statements” within the meaning of applicable Canadian securities regulations. The words “potential” and “estimated” and other expressions which are predictions of or indicate future events, trends or prospects and which do not relate to historical matters, identify forward-looking information. Although the Company believes that its anticipated future results, performance or achievements expressed or implied by the forward-looking statements and information are based upon reasonable assumptions and expectations, the reader should not place undue reliance on forward-looking statements and information because they involve known and unknown risks, uncertainties and other factors, many of which are beyond its control, which may cause the actual results, performance or achievements of the Company to differ materially from anticipated future results, performance or achievement expressed or implied by such forward-looking statements and information. Factors that could cause actual results to differ materially from those contemplated or implied by forward‐looking statements and information include, but are not limited to: the financial performance of Brookfield Corporation, the impact or unanticipated impact of general economic, political and market factors; the behavior of financial markets, including fluctuations in interest and foreign exchanges rates; limitations on the liquidity of our investments; global equity and capital markets and the availability of equity and debt financing and refinancing within these markets; strategic actions including dispositions; changes in accounting policies and methods used to report financial condition (including uncertainties associated with critical accounting assumptions and estimates); the effect of applying future accounting changes; business competition; operational and reputational risks; technological change; changes in government regulation and legislation; changes in tax laws; risks associated with the use of financial leverage; catastrophic events, such as earthquakes and hurricanes; the possible impact of international conflicts and other developments including terrorist acts; and other risks and factors detailed from time to time in the Company’s documents filed with the securities regulators in Canada. The Company cautions that the foregoing list of important factors that may affect future results is not exhaustive. When relying on the Company’s forward-looking statements and information, investors and others should carefully consider the foregoing factors and other uncertainties and potential events. Except as required by law, the Company undertakes no obligation to publicly update or revise any forward-looking statements and information, whether written or oral, that may be as a result of new information, future events or otherwise. The post Partners Value Investments Inc. Announces 2024 Annual Results appeared first on ForexTV.

Read More

Senvest Capital Reports Results for the Year Ended December 31, 2024

MONTREAL, March 28, 2025 (GLOBE NEWSWIRE) -- Senvest Capital Inc. today reported net income attributable to common shareholders of $258.1 million or $105.06 per share for the year ended December 31, 2024. This compares to net income attributable to common shareholders of $83.6 million or $33.78 per share for the year 2023. Financial statements are available online at Sedar www.sedarplus.ca   CONSOLIDATED STATEMENTS OF INCOME   (in millions of dollars, except per share amounts)   For the years ended         December 31, 2024 December 31, 2023       Net income attributable to common shareholders $258.1 $83.6       Diluted earnings per share attributable to common shareholders $105.06 $33.78       Contact: George Malikotsis, Vice President Finance(514) 281-8082 The post Senvest Capital Reports Results for the Year Ended December 31, 2024 appeared first on ForexTV.

Read More

Truss Faber Welcomes International Trade and Regulatory Attorney, Suzanne Garner

SEATTLE, March 28, 2025 (GLOBE NEWSWIRE) -- Truss Faber PC is pleased to welcome Suzanne Garner, an experienced attorney specializing in international trade, regulatory compliance, and dispute resolution, to its team of senior-level attorneys and legal advisors. With almost two decades of both federal government and private practice legal experience, including her tenure as associate general counsel at the Office of the U.S. Trade Representative and as a litigation associate at a top global law firm, Garner brings unparalleled insight into international trade policy, government investigations, and global economic regulatory frameworks. At Truss Faber, Garner will advise clients on international trade matters, regulatory compliance, and complex dispute resolution. Her extensive background includes representing the United States in global trade negotiations and WTO disputes, defending companies in international arbitration and anti-corruption investigations, and conducting independent workplace investigations involving claims of corporate misconduct. “Joining Truss Faber is an excellent opportunity to be part of a talented team helping businesses navigate the complex legal issues arising in cross-border commerce,” said Garner. “I look forward to applying my experience to support clients in resolving disputes, mitigating risks, and achieving strategic business goals.” Garner earned her Juris Doctor from Boston College Law School and holds a Master of Arts from the University of California, Santa Barbara. She is licensed to practice law in Washington and California. For more information about Truss Faber PC and its legal services, visit www.trussfaber.com. About Truss Faber:Truss Faber PC provides legal counsel to the construction and manufacturing industries and companies involved in government contracts. Truss Faber’s senior-level team has deep experience and a proven track record of prioritizing results and efficiency over red tape, delivering clever solutions to complex legal problems. Find more at www.trussfaber.com. Media Contact:Kristi Herriott206.466.2702Kristi@firmani.com The post Truss Faber Welcomes International Trade and Regulatory Attorney, Suzanne Garner appeared first on ForexTV.

Read More

Euronext publishes its 2024 Universal Registration Document

Euronext publishes its 2024 Universal Registration Document Amsterdam, Brussels, Dublin, Lisbon, Milan, Oslo and Paris – 28 March 2025 – Euronext, the leading pan-European market infrastructure, today announces that it has filed its 2024 Universal Registration Document, prepared in ESEF format (European Single Electronic Format), including the 2024 Annual Financial Statements and Directors’ Report to the Stichting Autoriteit Financiële Markten (the “AFM”), on 28 March 2025, as competent authority under Regulation (EU) 2017/1129. The 2024 Universal Registration Document has been filed in English and is available in ESEF format on Euronext’s website at:https://www.euronext.com/en/investor-relations/financial-information/financial-reports Printed copies of the official version filed to the AFM in ESEF format are available at the registered office of Euronext N.V.: Beursplein 5 1012 JW Amsterdam The Netherlands. CONTACTS   ANALYSTS & INVESTORS – ir@euronext.com Investor Relations        Aurélie Cohen                          Judith Stein        +33 6 15 23 91 97           MEDIA – mediateam@euronext.com  Europe        Aurélie Cohen         +33 1 70 48 24 45            Andrea Monzani         +39 02 72 42 62 13  Belgium        Marianne Aalders         +32 26 20 15 01                  France, Corporate        Flavio Bornancin-Tomasella        +33 1 70 48 24 45                  Ireland        Andrea Monzani         +39 02 72 42 62 13                  Italy         Ester Russom         +39 02 72 42 67 56                  The Netherlands        Marianne Aalders         +31 20 721 41 33                  Norway         Cathrine Lorvik Segerlund        +47 41 69 59 10                  Portugal         Sandra Machado        +351 91 777 68 97                                 About Euronext   Euronext is the leading European capital market infrastructure, covering the entire capital markets value chain, from listing, trading, clearing, settlement and custody, to solutions for issuers and investors. Euronext runs MTS, one of Europe’s leading electronic fixed income trading markets, and Nord Pool, the European power market. Euronext also provides clearing and settlement services through Euronext Clearing and its Euronext Securities CSDs in Denmark, Italy, Norway and Portugal. As of December 2024, Euronext’s regulated exchanges in Belgium, France, Ireland, Italy, the Netherlands, Norway and Portugal host over 1,800 listed issuers with around €6 trillion in market capitalisation, a strong blue-chip franchise and the largest global centre for debt and fund listings. With a diverse domestic and international client base, Euronext handles 25% of European lit equity trading. Its products include equities, FX, ETFs, bonds, derivatives, commodities and indices. For the latest news, go to euronext.com or follow us on X and LinkedIn. Disclaimer This press release is for information purposes only: it is not a recommendation to engage in investment activities and is provided “as is”, without representation or warranty of any kind. While all reasonable care has been taken to ensure the accuracy of the content, Euronext does not guarantee its accuracy or completeness. Euronext will not be held liable for any loss or damages of any nature ensuing from using, trusting or acting on information provided. No information set out or referred to in this publication may be regarded as creating any right or obligation. The creation of rights and obligations in respect of financial products that are traded on the exchanges operated by Euronext’s subsidiaries shall depend solely on the applicable rules of the market operator. All proprietary rights and interest in or connected with this publication shall vest in Euronext. This press release speaks only as of this date. Euronext refers to Euronext N.V. and its affiliates. Information regarding trademarks and intellectual property rights of Euronext is available at www.euronext.com/terms-use. © 2025, Euronext N.V. - All rights reserved.  The Euronext Group processes your personal data in order to provide you with information about Euronext (the "Purpose"). With regard to the processing of this personal data, Euronext will comply with its obligations under Regulation (EU) 2016/679 of the European Parliament and Council of 27 April 2016 (General Data Protection Regulation, “GDPR”), and any applicable national laws, rules and regulations implementing the GDPR, as provided in its privacy statement available at: www.euronext.com/privacy-policy. In accordance with the applicable legislation you have rights with regard to the processing of your personal data: for more information on your rights, please refer to: www.euronext.com/data_subjects_rights_request_information. To make a request regarding the processing of your data or to unsubscribe from this press release service, please use our data subject request form at connect2.euronext.com/form/data-subjects-rights-request or email our Data Protection Officer at dpo@euronext.com. Attachment Euronext_URD 2024 Publication The post Euronext publishes its 2024 Universal Registration Document appeared first on ForexTV.

Read More

Showing 2141 to 2160 of 2169 entries

You might be interested in the following

Keyword News · Community News · Twitter News

DDH honours the copyright of news publishers and, with respect for the intellectual property of the editorial offices, displays only a small part of the news or the published article. The information here serves the purpose of providing a quick and targeted overview of current trends and developments. If you are interested in individual topics, please click on a news item. We will then forward you to the publishing house and the corresponding article.
· Actio recta non erit, nisi recta fuerit voluntas ·